Literature DB >> 3815312

Malignant lymphoma in the X-linked lymphoproliferative syndrome.

D S Harrington, D D Weisenburger, D T Purtilo.   

Abstract

Male patients with the X-linked lymphoproliferative syndrome (XLP) have an inherited immune deficiency to Epstein-Barr virus (EBV) infection that results in fatal infectious mononucleosis (IM), acquired hypogammaglobulinemia- or agammaglobulinemia, virus-associated hemophagocytic syndrome, and non-Hodgkin's malignant lymphoma (ML). A clinicopathologic analysis of 17 patients with XLP who developed ML was performed. The median age of the patients at the time of diagnosis was 4.0 years (range, 2-19 years). The median overall survival was 12 months (range, 1-216 months). Eight patients had maternally related male relatives with ML. Other phenotypes of XLP were documented in male relatives of the remaining nine patients. Common presenting symptoms were fever, nausea, vomiting, and abdominal pain. Nine patients had "B" symptoms. All ML occurred at extranodal sites. The intestines, most commonly ileocecal, were involved in 76.5% of the cases. Thirteen patients had localized disease (Stages I and II) and four patients had advanced disease (Stages III and IV). A diffuse histologic pattern of growth was observed in all cases. The distribution of histologic subtypes included small noncleaved (41.2%), large noncleaved (17.6%), immunoblastic (17.6%), small cleaved or mixed cell (11.8%), and unclassifiable (5.9%) ML. Surgical resection, radiation therapy, and chemotherapy resulted in disease-free survivals of up to 192 months in eight patients (median 114 months; range, 12-192 months). Eight of 17 patients (47%) are still alive. A median survival of only 6.0 months (range, 1-12 months) was observed in the nine patients who died. No residual ML was found at autopsy. The small noncleaved subtype had an adverse prognosis (seven of nine deaths versus one of eight survivors; P less than 0.05). Bacterial infection was the major cause of death (seven of nine patients). Characteristics that distinguish ML in XLP from other ML include a maternal family history of XLP, early age of onset, acquired hypogammaglobulinemia, post-EBV infection, and ileocecal involvement.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3815312     DOI: 10.1002/1097-0142(19870415)59:8<1419::aid-cncr2820590807>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency.

Authors:  Rebecca A Marsh; Jack J Bleesing; Alexandra H Filipovich
Journal:  J Immunol Methods       Date:  2010-09-09       Impact factor: 2.303

Review 3.  SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions.

Authors:  Cynthia Detre; Marton Keszei; Xavier Romero; George C Tsokos; Cox Terhorst
Journal:  Semin Immunopathol       Date:  2010-02-10       Impact factor: 9.623

4.  Molecular genetic haplotype segregation studies in three families with X-linked lymphoproliferative disease.

Authors:  V Schuster; S Seidenspinner; T Grimm; W Kress; S Zielen; M Bock; H W Kreth
Journal:  Eur J Pediatr       Date:  1994-06       Impact factor: 3.183

Review 5.  Epstein-Barr virus and human diseases: recent advances in diagnosis.

Authors:  M Okano; G M Thiele; J R Davis; H L Grierson; D T Purtilo
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

6.  Characteristics of submucosal lymphoid tissue located in the proximal colon of the rat.

Authors:  D A Crouse; G A Perry; B O Murphy; J G Sharp
Journal:  J Anat       Date:  1989-02       Impact factor: 2.610

Review 7.  X-linked lymphoproliferative disease: genetic lesions and clinical consequences.

Authors:  Andrew J MacGinnitie; Raif Geha
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

8.  Emergence of anti-red blood cell antibodies triggers red cell phagocytosis by activated macrophages in a rabbit model of Epstein-Barr virus-associated hemophagocytic syndrome.

Authors:  Wen-Chuan Hsieh; Yao Chang; Mei-Chi Hsu; Bau-Shin Lan; Guan-Chung Hsiao; Huai-Chia Chuang; Ih-Jen Su
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

9.  Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome.

Authors:  K E Nichols; D P Harkin; S Levitz; M Krainer; K A Kolquist; C Genovese; A Bernard; M Ferguson; L Zuo; E Snyder; A J Buckler; C Wise; J Ashley; M Lovett; M B Valentine; A T Look; W Gerald; D E Housman; D A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

10.  Comparative pathobiology of macaque lymphocryptoviruses.

Authors:  Angela Carville; Keith G Mansfield
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.